Medical countermeasures against henipaviruses: a review and public health perspective
Henipaviruses, including Nipah virus, are regarded as pathogens of notable epidemic potential because of their high pathogenicity and the paucity of specific medical countermeasures to control infections in humans. We review the evidence of medical countermeasures against henipaviruses and project t...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2022-01, Vol.22 (1), p.e13-e27 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e27 |
|---|---|
| container_issue | 1 |
| container_start_page | e13 |
| container_title | The Lancet infectious diseases |
| container_volume | 22 |
| creator | Gómez Román, Raúl Tornieporth, Nadia Cherian, Neil George Shurtleff, Amy C L’Azou Jackson, Maïna Yeskey, Debra Hacker, Adam Mungai, Eric Le, Tung Thanh |
| description | Henipaviruses, including Nipah virus, are regarded as pathogens of notable epidemic potential because of their high pathogenicity and the paucity of specific medical countermeasures to control infections in humans. We review the evidence of medical countermeasures against henipaviruses and project their cost in a post-COVID-19 era. Given the sporadic and unpredictable nature of henipavirus outbreaks, innovative strategies will be needed to circumvent the infeasibility of traditional phase 3 clinical trial regulatory pathways. Stronger partnerships with scientific institutions and regulatory authorities in low-income and middle-income countries can inform coordination of appropriate investments and development of strategies and normative guidelines for the deployment and equitable use of multiple medical countermeasures. Accessible measures should include global, regional, and endemic in-country stockpiles of reasonably priced small molecules, monoclonal antibodies, and vaccines as part of a combined collection of products that could help to control henipavirus outbreaks and prevent future pandemics. |
| doi_str_mv | 10.1016/S1473-3099(21)00400-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8694750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S147330992100400X</els_id><sourcerecordid>2594293231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-9717d56b5f77682bd5f6dc55b966853ed58499a3bd71473d5eeffff5d40510573</originalsourceid><addsrcrecordid>eNqFkU1v1DAQQK0K1C_4CaBIXMohrZ147JhDq6oCilTEASr1Zjn2pOsq66R2shX_vt7dUgGX-mLL8zyemUfIO0aPGWXi5Cfjsi5rqtRRxT5Syiktb3bIfr7mJecgX23OW2SPHKR0RymTjPJdslfnAEil9sn1d3Temr6wwxwmjEs0aY6YCnNrfEhTscDgR7PycU6YPhWmiLjy-FCY4IpxbntvM2L6aVGMGNOIdvIrfENed6ZP-PZpPyTXXz7_urgsr358_XZxflVarmAqlWTSgWihk1I0VeugE84CtEqIBmp00HClTN06uW7FAWKXFzhOgVGQ9SE53ebNlSzRWQxTNL0eo1-a-FsPxut_I8Ev9O2w0o1QXALNCY6eEsThfsY06aVPFvveBBzmpCtQvFJ1VbOMfvgPvRvmGHJ7uhKsEqqhEjIFW8rGIaWI3XMxjOq1OL0Rp9dWdMX0Rpy-ye_e_93J86s_pjJwtgUwzzMbiDpZj8FmfTEPXbvBv_DFI3CKqcA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2612698075</pqid></control><display><type>article</type><title>Medical countermeasures against henipaviruses: a review and public health perspective</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Gómez Román, Raúl ; Tornieporth, Nadia ; Cherian, Neil George ; Shurtleff, Amy C ; L’Azou Jackson, Maïna ; Yeskey, Debra ; Hacker, Adam ; Mungai, Eric ; Le, Tung Thanh</creator><creatorcontrib>Gómez Román, Raúl ; Tornieporth, Nadia ; Cherian, Neil George ; Shurtleff, Amy C ; L’Azou Jackson, Maïna ; Yeskey, Debra ; Hacker, Adam ; Mungai, Eric ; Le, Tung Thanh</creatorcontrib><description>Henipaviruses, including Nipah virus, are regarded as pathogens of notable epidemic potential because of their high pathogenicity and the paucity of specific medical countermeasures to control infections in humans. We review the evidence of medical countermeasures against henipaviruses and project their cost in a post-COVID-19 era. Given the sporadic and unpredictable nature of henipavirus outbreaks, innovative strategies will be needed to circumvent the infeasibility of traditional phase 3 clinical trial regulatory pathways. Stronger partnerships with scientific institutions and regulatory authorities in low-income and middle-income countries can inform coordination of appropriate investments and development of strategies and normative guidelines for the deployment and equitable use of multiple medical countermeasures. Accessible measures should include global, regional, and endemic in-country stockpiles of reasonably priced small molecules, monoclonal antibodies, and vaccines as part of a combined collection of products that could help to control henipavirus outbreaks and prevent future pandemics.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(21)00400-X</identifier><identifier>PMID: 34735799</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Animals ; Chiroptera - virology ; Clinical Trials, Phase III as Topic ; Combined vaccines ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 vaccines ; Development strategies ; Disease Outbreaks - prevention & control ; Disease prevention ; Disease transmission ; Encephalitis ; Epidemics ; Henipavirus - classification ; Henipavirus - pathogenicity ; Henipavirus Infections - drug therapy ; Henipavirus Infections - prevention & control ; Henipavirus Infections - transmission ; Humans ; Income ; Infections ; Infectious diseases ; Medical Countermeasures ; Monoclonal antibodies ; Nipah virus ; Nipah Virus - pathogenicity ; Outbreaks ; Pandemics ; Pathogenicity ; Pathogens ; Public domain ; Public Health ; R&D ; Regulatory agencies ; Research & development ; Review ; SARS-CoV-2 - pathogenicity ; Viruses</subject><ispartof>The Lancet infectious diseases, 2022-01, Vol.22 (1), p.e13-e27</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><rights>2022. Elsevier Ltd</rights><rights>2021 Published by Elsevier Ltd. 2022 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-9717d56b5f77682bd5f6dc55b966853ed58499a3bd71473d5eeffff5d40510573</citedby><cites>FETCH-LOGICAL-c495t-9717d56b5f77682bd5f6dc55b966853ed58499a3bd71473d5eeffff5d40510573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S147330992100400X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34735799$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez Román, Raúl</creatorcontrib><creatorcontrib>Tornieporth, Nadia</creatorcontrib><creatorcontrib>Cherian, Neil George</creatorcontrib><creatorcontrib>Shurtleff, Amy C</creatorcontrib><creatorcontrib>L’Azou Jackson, Maïna</creatorcontrib><creatorcontrib>Yeskey, Debra</creatorcontrib><creatorcontrib>Hacker, Adam</creatorcontrib><creatorcontrib>Mungai, Eric</creatorcontrib><creatorcontrib>Le, Tung Thanh</creatorcontrib><title>Medical countermeasures against henipaviruses: a review and public health perspective</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Henipaviruses, including Nipah virus, are regarded as pathogens of notable epidemic potential because of their high pathogenicity and the paucity of specific medical countermeasures to control infections in humans. We review the evidence of medical countermeasures against henipaviruses and project their cost in a post-COVID-19 era. Given the sporadic and unpredictable nature of henipavirus outbreaks, innovative strategies will be needed to circumvent the infeasibility of traditional phase 3 clinical trial regulatory pathways. Stronger partnerships with scientific institutions and regulatory authorities in low-income and middle-income countries can inform coordination of appropriate investments and development of strategies and normative guidelines for the deployment and equitable use of multiple medical countermeasures. Accessible measures should include global, regional, and endemic in-country stockpiles of reasonably priced small molecules, monoclonal antibodies, and vaccines as part of a combined collection of products that could help to control henipavirus outbreaks and prevent future pandemics.</description><subject>Animals</subject><subject>Chiroptera - virology</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Combined vaccines</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>Development strategies</subject><subject>Disease Outbreaks - prevention & control</subject><subject>Disease prevention</subject><subject>Disease transmission</subject><subject>Encephalitis</subject><subject>Epidemics</subject><subject>Henipavirus - classification</subject><subject>Henipavirus - pathogenicity</subject><subject>Henipavirus Infections - drug therapy</subject><subject>Henipavirus Infections - prevention & control</subject><subject>Henipavirus Infections - transmission</subject><subject>Humans</subject><subject>Income</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Medical Countermeasures</subject><subject>Monoclonal antibodies</subject><subject>Nipah virus</subject><subject>Nipah Virus - pathogenicity</subject><subject>Outbreaks</subject><subject>Pandemics</subject><subject>Pathogenicity</subject><subject>Pathogens</subject><subject>Public domain</subject><subject>Public Health</subject><subject>R&D</subject><subject>Regulatory agencies</subject><subject>Research & development</subject><subject>Review</subject><subject>SARS-CoV-2 - pathogenicity</subject><subject>Viruses</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkU1v1DAQQK0K1C_4CaBIXMohrZ147JhDq6oCilTEASr1Zjn2pOsq66R2shX_vt7dUgGX-mLL8zyemUfIO0aPGWXi5Cfjsi5rqtRRxT5Syiktb3bIfr7mJecgX23OW2SPHKR0RymTjPJdslfnAEil9sn1d3Temr6wwxwmjEs0aY6YCnNrfEhTscDgR7PycU6YPhWmiLjy-FCY4IpxbntvM2L6aVGMGNOIdvIrfENed6ZP-PZpPyTXXz7_urgsr358_XZxflVarmAqlWTSgWihk1I0VeugE84CtEqIBmp00HClTN06uW7FAWKXFzhOgVGQ9SE53ebNlSzRWQxTNL0eo1-a-FsPxut_I8Ev9O2w0o1QXALNCY6eEsThfsY06aVPFvveBBzmpCtQvFJ1VbOMfvgPvRvmGHJ7uhKsEqqhEjIFW8rGIaWI3XMxjOq1OL0Rp9dWdMX0Rpy-ye_e_93J86s_pjJwtgUwzzMbiDpZj8FmfTEPXbvBv_DFI3CKqcA</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Gómez Román, Raúl</creator><creator>Tornieporth, Nadia</creator><creator>Cherian, Neil George</creator><creator>Shurtleff, Amy C</creator><creator>L’Azou Jackson, Maïna</creator><creator>Yeskey, Debra</creator><creator>Hacker, Adam</creator><creator>Mungai, Eric</creator><creator>Le, Tung Thanh</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><general>Published by Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220101</creationdate><title>Medical countermeasures against henipaviruses: a review and public health perspective</title><author>Gómez Román, Raúl ; Tornieporth, Nadia ; Cherian, Neil George ; Shurtleff, Amy C ; L’Azou Jackson, Maïna ; Yeskey, Debra ; Hacker, Adam ; Mungai, Eric ; Le, Tung Thanh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-9717d56b5f77682bd5f6dc55b966853ed58499a3bd71473d5eeffff5d40510573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Chiroptera - virology</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Combined vaccines</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>Development strategies</topic><topic>Disease Outbreaks - prevention & control</topic><topic>Disease prevention</topic><topic>Disease transmission</topic><topic>Encephalitis</topic><topic>Epidemics</topic><topic>Henipavirus - classification</topic><topic>Henipavirus - pathogenicity</topic><topic>Henipavirus Infections - drug therapy</topic><topic>Henipavirus Infections - prevention & control</topic><topic>Henipavirus Infections - transmission</topic><topic>Humans</topic><topic>Income</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Medical Countermeasures</topic><topic>Monoclonal antibodies</topic><topic>Nipah virus</topic><topic>Nipah Virus - pathogenicity</topic><topic>Outbreaks</topic><topic>Pandemics</topic><topic>Pathogenicity</topic><topic>Pathogens</topic><topic>Public domain</topic><topic>Public Health</topic><topic>R&D</topic><topic>Regulatory agencies</topic><topic>Research & development</topic><topic>Review</topic><topic>SARS-CoV-2 - pathogenicity</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez Román, Raúl</creatorcontrib><creatorcontrib>Tornieporth, Nadia</creatorcontrib><creatorcontrib>Cherian, Neil George</creatorcontrib><creatorcontrib>Shurtleff, Amy C</creatorcontrib><creatorcontrib>L’Azou Jackson, Maïna</creatorcontrib><creatorcontrib>Yeskey, Debra</creatorcontrib><creatorcontrib>Hacker, Adam</creatorcontrib><creatorcontrib>Mungai, Eric</creatorcontrib><creatorcontrib>Le, Tung Thanh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez Román, Raúl</au><au>Tornieporth, Nadia</au><au>Cherian, Neil George</au><au>Shurtleff, Amy C</au><au>L’Azou Jackson, Maïna</au><au>Yeskey, Debra</au><au>Hacker, Adam</au><au>Mungai, Eric</au><au>Le, Tung Thanh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medical countermeasures against henipaviruses: a review and public health perspective</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>22</volume><issue>1</issue><spage>e13</spage><epage>e27</epage><pages>e13-e27</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><abstract>Henipaviruses, including Nipah virus, are regarded as pathogens of notable epidemic potential because of their high pathogenicity and the paucity of specific medical countermeasures to control infections in humans. We review the evidence of medical countermeasures against henipaviruses and project their cost in a post-COVID-19 era. Given the sporadic and unpredictable nature of henipavirus outbreaks, innovative strategies will be needed to circumvent the infeasibility of traditional phase 3 clinical trial regulatory pathways. Stronger partnerships with scientific institutions and regulatory authorities in low-income and middle-income countries can inform coordination of appropriate investments and development of strategies and normative guidelines for the deployment and equitable use of multiple medical countermeasures. Accessible measures should include global, regional, and endemic in-country stockpiles of reasonably priced small molecules, monoclonal antibodies, and vaccines as part of a combined collection of products that could help to control henipavirus outbreaks and prevent future pandemics.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>34735799</pmid><doi>10.1016/S1473-3099(21)00400-X</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2022-01, Vol.22 (1), p.e13-e27 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8694750 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Chiroptera - virology Clinical Trials, Phase III as Topic Combined vaccines Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 vaccines Development strategies Disease Outbreaks - prevention & control Disease prevention Disease transmission Encephalitis Epidemics Henipavirus - classification Henipavirus - pathogenicity Henipavirus Infections - drug therapy Henipavirus Infections - prevention & control Henipavirus Infections - transmission Humans Income Infections Infectious diseases Medical Countermeasures Monoclonal antibodies Nipah virus Nipah Virus - pathogenicity Outbreaks Pandemics Pathogenicity Pathogens Public domain Public Health R&D Regulatory agencies Research & development Review SARS-CoV-2 - pathogenicity Viruses |
| title | Medical countermeasures against henipaviruses: a review and public health perspective |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A19%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medical%20countermeasures%20against%20henipaviruses:%20a%20review%20and%20public%20health%20perspective&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=G%C3%B3mez%20Rom%C3%A1n,%20Ra%C3%BAl&rft.date=2022-01-01&rft.volume=22&rft.issue=1&rft.spage=e13&rft.epage=e27&rft.pages=e13-e27&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(21)00400-X&rft_dat=%3Cproquest_pubme%3E2594293231%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2612698075&rft_id=info:pmid/34735799&rft_els_id=S147330992100400X&rfr_iscdi=true |